RALLYBIO CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
RALLYBIO CORPORATION (RLYB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 32.36 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-26
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 32.36K shares, a 97.93% decline year-over-year.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -1.57M shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.12M shares, a 44.52% decline from fiscal 2023.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.02M shares, a 38.28% increase from fiscal 2022.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.46M shares, a 7.44% increase from fiscal 2021.
- RALLYBIO CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.36M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | 32.36K shares S-4/A · filed 2026-08-26 | -1.54M shares derived: sum of 3 quarters · filed 2026-08-26 | -1.54M shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | 32.36K shares S-4 · filed 2026-07-15 | -1.54M shares derived: sum of 2 quarters · filed 2026-08-26 | -1.54M shares derived: sum of 3 quarters · filed 2026-08-26 | -1.31M shares derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | -1.57M shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -1.57M shares derived: sum of 2 quarters · filed 2026-08-26 | -1.34M shares derived: sum of 3 quarters · filed 2026-08-26 | 224.18K shares S-4/A · filed 2026-08-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 228.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.79M shares 10-Q · filed 2025-11-06 | 1.79M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 228.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.79M shares 10-Q · filed 2025-08-07 | 1.79M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.79M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.57M shares 10-Q · filed 2025-05-08 | 1.57M shares derived: sum of 2 quarters · filed 2025-05-08 | 1.57M shares derived: sum of 3 quarters · filed 2025-05-08 | 1.70M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-13 | 132.00K shares derived: sum of 3 quarters · filed 2025-03-13 | 1.12M shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 132.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 1.12M shares 10-Q · filed 2024-11-07 | 1.12M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 132.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.12M shares 10-Q · filed 2024-08-08 | 1.12M shares derived: sum of 3 quarters · filed 2024-08-08 | 1.13M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 987.04K shares 10-Q · filed 2024-05-09 | 987.04K shares derived: sum of 2 quarters · filed 2024-05-09 | 994.99K shares derived: sum of 3 quarters · filed 2024-05-09 | 1.14M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 7.95K shares derived: sum of 2 quarters · filed 2024-03-12 | 153.03K shares derived: sum of 3 quarters · filed 2024-03-12 | 2.02M shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 7.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 153.03K shares derived: sum of 2 quarters · filed 2023-11-09 | 2.02M shares 10-Q · filed 2023-11-09 | 2.02M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 145.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.01M shares 10-Q · filed 2023-08-08 | 2.01M shares derived: sum of 3 quarters · filed 2023-08-08 | 2.08M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 1.86M shares 10-Q · filed 2023-05-09 | 1.86M shares derived: sum of 2 quarters · filed 2023-05-09 | 1.93M shares derived: sum of 3 quarters · filed 2023-05-09 | 2.23M shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 65.81K shares derived: sum of 2 quarters · filed 2023-03-06 | 367.14K shares derived: sum of 3 quarters · filed 2023-03-06 | 1.46M shares 10-K · filed 2023-03-06 |
| 2022-09-30 | 65.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 367.14K shares derived: sum of 2 quarters · filed 2022-11-07 | 1.46M shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 301.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 1.39M shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 1.09M shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 1.36M shares 10-K · filed 2022-03-15 | |||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 0.00 shares 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 0.00 shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-15 | |||
| 2018-12-31 | 4.50M shares 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |